Effects of Urate-Lowering Therapy on Risk of Hyperlipidemia in Gout by a Population-Based Cohort Study and on In Vitro Hepatic Lipogenesis-Related Gene Expression

Table 3

Comparison of incidence and hazard ratio of hyperlipidemia stratified by sex, age, and comorbidity between patients with and without gout.

Variable	Gout						Crude HR (95% CI)	Adjusted HR^† (95% CI)
	No			Yes
	Event	PY	Rate^#	Event	PY	Rate^#
All	24485	1378799	17.8	13639	293172	46.5	2.61 (2.55, 2.66)	2.55 (2.50, 2.61)
Sex
Female	7080	282065	25.1	3217	59166	54.4	2.14 (2.06, 2.23)	2.15 (2.06, 2.24)
Male	17405	1096734	15.9	10422	234006	44.5	2.80 (2.73, 2.87)	2.70 (2.64, 2.77)
Stratified age
≤49	10087	850974	11.9	7382	191709	40.6	3.44 (3.34, 3.55)	3.08 (2.99, 3.18)
50-64	9290	312176	29.8	4160	63233	65.8	2.19 (2.11, 2.27)	2.18 (2.10, 2.26)
65+	5108	215649	23.7	2097	48229	43.5	1.82 (1.73, 1.91)	1.88 (1.79, 1.98)
Comorbidity^‡
No	13645	1003452	13.6	10840	375347	28.9	3.40 (3.31, 3.49)	3.37 (3.28, 3.46)
Yes	8639	181008	47.7	5000	112164	44.6	1.57 (1.52, 1.62)	1.54 (1.49, 1.60)

PY: person-years; Rate^#: incidence rate, per 1,000 person-years; Crude HR: crude hazard ratio; Adjusted HR^†: multivariable analysis including age, sex, and comorbidities of hypertension, stroke, diabetes, COPD, CAD, alcohol-related illness, and asthma; Comorbidity^‡: patients with any one of the comorbidities of hypertension, stroke, diabetes, COPD, CAD, alcohol-related illness, and asthma were classified as the comorbidity group. .